





FIG. 1

FIG. 2










FIG. 3










FIG. 6







FIG. 7






FIG. 8F




FIG. 8E








FIG. 8D








FIG. 10




FIG. 11




FIG. 12B

FIG. 12A




FIG. 13A




FIG. 13B







FIG. 13C

	GIGA-564	Ipilimumab	CD80	CD86
R70		X	X	X
K130	X	X	X	X
Y139	X	X	X	X
L141	X	X		
I143	X	X	X	X

FIG. 13D






FIG. 15A

FIG. 15B





FIG. 15C






FIG. 15D




FIG. 15E




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 19




FIG. 20A




FIG. 20B




FIG. 20C

FIG. 20D





FIG. 20D (Cont.)






FIG. 20E




FIG. 21




FIG. 22B




FIG. 22A




FIG. 22D




FIG. 22C




FIG. 23B




FIG. 23A




FIG. 23D





FIG. 23C

FIG. 24A







FIG. 24B






FIG. 24D




FIG. 24C




FIG. 24E




FIG. 25B




FIG. 25A




FIG. 25D

FIG. 25C




FIG. 25E




FIG. 26

Fc effector function in anti-CTLA-4 is necessary for
robust anti-tumor responses¹




FIG. 27




FIG. 28

CTLA-4 cell-based
signaling assay




FIG. 29




FIG. 30




FIG. 31




FIG. 32

FIG. 33




FIG. 34




FIG. 34 (CONTINUED)




FIG. 34 (CONTINUED)






FIG. 35



Sample Name	Subset Name	Surface Expression Marker	Stain	Count
01-Well-B1.fcs	Live Cells	hCTLA4	GG-584 + ahlgG	48515
01-Well-B3.fcs	Live Cells	hCTLA4	Alexo + ahlgG	48841



Sample Name	Subset Name	Surface Expression Marker	Stain	Count
01-Well-B2.fcs	Live Cells	hCTLA4	Ipi + ahlgG	48
01-Well-B3.fcs	Live Cells	hCTLA4	Alexo + ahlgG	48

FIG. 35 (CONTINUED)




FIG. 35 (CONTINUED)




FIG. 35 (CONTINUED)




FIG. 36A




FIG. 36B




FIG. 36C




FIG. 36D




FIG. 36E




FIG. 37




FIG. 38




FIG. 39




FIG. 40




FIG. 40 (CONTINUED)




FIG. 41




FIG. 42A




FIG. 42B




FIG. 43A

IgG Heavy chain domain
IMGT exon numbering
EU numbering

CH1
95 96 97 98
212 213 214 215

IgG1 allotypes
IGHG1*08
IGHG1*01

D	K	R	V
D	K	K	V

FIG. 43B

